![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Accepts Clinical Research Plan for Senzer’s Inhaler
FDA Accepts Clinical Research Plan for Senzer’s Inhaler
![FDA_Logo_Black_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Black_2016.gif?t=1579040596&width=430)
April 30, 2018
The FDA accepted an application for a clinical development study on Dronabinol inhalation using Senzer’s inhaler device, a breath-activated inhaler.
The approval means the clinical program will begin to explore vomiting and chemotherapy-induced nausea in adult cancer patients who had suboptimal reactions to conventional antiemetics.
The program aims to validate how a pharmaceutical version of Dronabinol, an FDA-approved cannabinoid being developed by Insys, can be delivered through Senzer’s inhaler device.
Upcoming Events
-
21Oct